What is Pendulum Therapeutics?
Pendulum Therapeutics is a pioneering microbiome company that leverages advanced DNA sequencing to develop interventions for specific diseases. Its lead product, Pendulum Glucose Control, is a clinically validated Medical Probiotic designed to aid in the dietary management of type 2 diabetes by influencing A1C and blood sugar levels through the microbiome. The company's proprietary platform facilitates the identification of microbiome mechanisms and accelerates the translation of discoveries into clinically validated products. Founded in 2012, Pendulum Therapeutics, formerly Whole Biome, is headquartered in San Francisco and is recognized for its evidence-based approach to microbiome science.
How much funding has Pendulum Therapeutics raised?
Pendulum Therapeutics has raised a total of $117.5M across 4 funding rounds:
Series A
$18.5M
Series B
$35M
Series C
$54M
Other Financing Round
$10M
Series A (2017): $18.5M with participation from Morgan Noble, Khosla Ventures, and True Ventures
Series B (2019): $35M led by Sequoia Capital
Series C (2021): $54M supported by Khosla Ventures, Meritech, True Ventures, and Steamboat Ventures
Other Financing Round (2023): $10M featuring Fonterra
Key Investors in Pendulum Therapeutics
Khosla Ventures
Khosla Ventures is a venture capital firm founded in 2004, specializing in breakthrough technologies across various sectors including health and sustainable energy. They provide venture assistance and strategic advice to entrepreneurs.
True Ventures
True Ventures is a founder-first venture capital firm that supports early-stage technology and artificial intelligence companies, offering capital, guidance, and community.
Sequoia Capital
Sequoia Capital is a global venture capital firm with a history of investing in market-leading technology companies. They partner with entrepreneurs to build enduring businesses across various stages of growth.
What's next for Pendulum Therapeutics?
With substantial enterprise-level backing and a recent strategic investment, Pendulum Therapeutics is poised for significant advancements. The company's focus on translating scientific discovery into commercialized microbiome interventions, particularly for metabolic diseases, suggests a strategic expansion into broader therapeutic areas. Future developments are likely to involve scaling production, further clinical validation, and potentially new product pipeline expansion, capitalizing on the growing interest and investment in the gut microbiome's role in human health.
See full Pendulum Therapeutics company page
